The Priority Review

Tag

HIV

1 story

  1. Clinical trials

    0.8% of adults with HIV-1 had HIV-1 RNA ≥50 copies/mL at Week 48 on bictegravir/lenacapavir

    At Week 48, 0.8% on bictegravir/lenacapavir and 1.1% on stable baseline therapy had HIV-1 RNA ≥50 copies/mL. The record adds Phase 3 comparative results for adults with suppressed HIV-1 on complex regimens.